Branched Hetero Monodispersed PEG Purification for ADC Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing branched type hetero monodispersed polyethylene glycol result in low functional group purity due to the presence of impurities with the same functional groups at both terminals, leading to decreased effectiveness in antibody-drug conjugates (ADCs) and potential side effects.
Innovation Solution
A method involving simple separatory extraction and specific base catalysts is used to synthesize branched type hetero monodispersed polyethylene glycol with different functional groups at both terminals, avoiding excessive conjugation of monodispersed polyethylene glycol to one branch site, and utilizing separatory purification to achieve high purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to produce branched type hetero monodispersed polyethylene glycol, then the production process is simple, but the functional group purity is low due to impurities with the same functional groups at both terminals
Solution Approach 1:
The production process is divided into multiple sequential steps: (1) coupling monodispersed polyethylene glycol with a compound having different functional groups at both terminals using a base catalyst, (2) separating the reaction mixture into organic and aqueous phases, (3) extracting the product into the organic phase, and (4) removing the base catalyst. This segmentation allows each step to address a specific aspect of purification, achieving high functional group purity without requiring complex equipment.
Solution Approach 2:
The invention employs liquid-liquid extraction to separate the desired branched type hetero monodispersed polyethylene glycol from impurities. The product is extracted into an organic solvent phase while impurities with the same functional groups at both terminals remain in the aqueous phase or are removed during the extraction process, thereby achieving high functional group purity through a relatively simple separation technique.
2Reliability
If impurities with the same functional groups at both terminals are present, then the production cost is reduced, but the effectiveness of ADCs decreases and side effects occur
Solution Approach 1:
The invention performs preliminary purification actions during the synthesis process itself. By incorporating separation and extraction steps immediately after the coupling reaction, the method removes impurities before they can cause problems in subsequent ADC conjugation. This preliminary action ensures high functional group purity in the final product, maintaining ADC effectiveness while keeping the overall process relatively simple.
3Manufacturing precision
If separatory purification is performed to achieve high purity, then the functional group purity increases, but the production time increases
Solution Approach 1:
The invention merges multiple functions into a single integrated process flow. The coupling reaction, separation, extraction, and catalyst removal are combined into a sequential process where each step prepares for the next. This merging allows the achievement of high functional group purity through relatively simple and rapid operations, minimizing the time penalty associated with purification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures high functional group purity, reducing the generation of compounds lacking either the desired antibody or drug, thereby enhancing the effectiveness of ADCs and minimizing side effects.
Implementation Method 1
using a base catalyst having a pKa in an aqueous solution of 15 to 20
Implementation Method 2
separatory purification
Data Source
AI summary
A method of producing a compound represented by formula (3):includes: step (1) of performing coupling of a monodispersed polyethylene glycol derivative represented by formula (4) shown below with a compound represented by formula (5) shown below using a base catalyst having a pKa in an aqueous solution of 15 to 20 to obtain a compound represented by formula (6) shown below, step (2) of deprotecting the protective group A of the compound represented by the formula (6) to obtain a compound represented by formula (7) shown below, and step (3) of subjecting the compound represented by the formula (7) to separatory purification; and step (4) of subjecting the compound represented by the formula (7) to deprotection treatment or reduction treatment to obtain the compound represented by formula (3), in an order described above, where Y2, n, A, B, and Z are as defined herein: